CRS-3123 is under clinical development by Crestone and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase II drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CRS-3123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CRS-3123 overview
CRS-3123 (REP-3123) is under development for the treatment of Clostridium difficile infections (CDI), graft-versus-host disease (GvHD) and Helicobacter pylori Infections. The therapeutic candidate is administered orally in form of capsule. It targets methionyl-tRNA synthetase (MetRS). It is a diaryldiamine antibiotic.
Crestone overview
Crestone is a biopharmaceutical company that discovers and develops small molecule drugs for serious bacterial infections. The company’s research and development pipeline includes CRS3123, CRS0540 Gram-positives DNA polymerase inhibitors, and CRS0393 NTM/TB. Its CRS3123 is a small molecule protein synthesis inhibitor, which is used for the treatment of Clostridium difficile infection. Crestone’s DNA polymerase inhibitors are used to treat gram-positive infections such as methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococci, and group A strep. The company’s NTM/TB is being developed targeting tuberculosis and non-tuberculous mycobacteria. Crestone is headquartered in Boulder, Colorado, the US.
For a complete picture of CRS-3123’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
